These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32958357)

  • 1. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
    Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
    Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study.
    Amini AE; Hunter AE; Almashad A; Feng AJ; Patel ND; O'Dea MR; McCormick SR; Rodgers LH; Salari K
    Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38453598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.
    Gulati R; Jiao B; Al-Faouri R; Sharma V; Kaul S; Fleishman A; Wymer K; Boorjian SA; Olumi AF; Etzioni R; Gershman B
    Ann Intern Med; 2024 Jul; 177(7):871-881. PubMed ID: 38830219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
    BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?
    Pepe P; Garufi A; Priolo G; Pennisi M
    Clin Genitourin Cancer; 2015 Feb; 13(1):e27-30. PubMed ID: 25081324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.
    Cremers RG; Eeles RA; Bancroft EK; Ringelberg-Borsboom J; Vasen HF; Van Asperen CJ; ; Schalken JA; Verhaegh GW; Kiemeney LA
    Urol Oncol; 2015 May; 33(5):202.e19-28. PubMed ID: 25746941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
    Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
    JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
    Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
    J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial.
    Arsov C; Albers P; Herkommer K; Gschwend J; Imkamp F; Peters I; Kuczyk M; Hadaschik B; Kristiansen G; Schimmöller L; Antoch G; Rummeny E; Wacker F; Schlemmer H; Benner A; Siener R; Kaaks R; Becker N
    Int J Cancer; 2022 Jun; 150(11):1861-1869. PubMed ID: 35076933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
    Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
    Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.